Xcout Intel
Scribe Therapeutics, Inc.
Scribe Therapeutics is a clinical-stage biotechnology company that develops genetic therapies for conditions such as heart disease and has pursued public offerings in the United States.
Subscribe to see Scribe Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Scribe Therapeutics, Inc. at a glance
Scribe Therapeutics, Inc. is a biotech company headquartered in Alameda, United States. It is publicly listed (SCTX) with a market capitalisation of $315.2M. Xcout tracks 11 named people at Scribe Therapeutics, Inc., including David L. Parrot (CFO & Treasurer).
Scribe Therapeutics, Inc. leadership
- David L. ParrotCFO & Treasurer
- Svetlana LucasChief Business Officer
- Benjamin L. OakesCo-Founder, President, CEO & Chairman
- Brett T. StaahlCo-Founder & VP of External Innovation
- David F. SavageCo-Founder & Scientific Advisor
- Jennifer A DoudnaCo-Founder & Scientific Advisor
5 more named people on record for Scribe Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Recent Scribe Therapeutics, Inc. news
- IPOScribe Therapeutics, investida da Eli Lilly, mira IPO de US$ 107,2 milhões nos EUA
- IPOScribe Therapeutics Inc. Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
7 corporate events on record, with sources — see the full timeline →
Scribe Therapeutics, Inc. competitors
A few of Scribe Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
AskBio is a clinical-stage gene therapy company that develops adeno-associated virus (AAV) gene therapies to treat genetic and complex disorders. The company focuses on advancing genetic medicine through its proprietary technology platforms, manufacturing processes, and clinical trials.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
Get Scribe Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Scribe Therapeutics, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 7 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access